


Hypothermia Protocols: A Focus on Bedside Application

Jennifer Gass, PharmD, MS, BCPS
Cardiology Critical Care Pharmacy Specialist II
Memorial Hermann - TMC




Objectives

- Describe the benefits of induced hypothermia following cardiac arrest
- Discuss key logistical items that must be considered prior to implementation of hypothermia protocols in clinical practice

Historical Perspective

Hippocrates - ~400 BC




Temple Fay - 1937

Bigelow & McBirnie - 1953

Rosomoff & Gilbert - 1955

Benson - 1959




Baron Dominique Larrey - 1812

Chest 2008; 132(5): 1267-1274

Therapeutic Hypothermia Today

- New England Journal of Medicine – 2002
 - 2 articles demonstrating improved outcomes in patients receiving therapeutic hypothermia
- Advisory Statement – 2003
 - American Heart Association (AHA) & International Liaison Committee on Resuscitation (ILCOR)
- ACLS Guidelines – 2010
 - Class I, LOE B
 - Class IIb, LOE B

Benefits of Therapeutic Hypothermia




N Engl J Med 2002; 346:549-556

Benefits of Therapeutic Hypothermia

- Multi-center, blinded, randomized controlled trial
- Hypothermia for 24 hours (32°C to 34°C) versus normothermia
- Witnessed arrest, Vfib or pulseless Vtach arrest, unresponsive after ROSC
- Primary end-point: favorable neurologic outcome within 6 months of arrest

N Engl J Med 2002; 346:549-556




Benefits of Therapeutic Hypothermia

TREATMENT OF COMATOSE SURVIVORS OF OUT-OF-HOSPITAL CARDIAC ARREST WITH INDUCED HYPOTHERMIA

STEVEN A. BERHANI, M.B., B.S., TAILOU W. GAY, M.B., B.S., MICHAEL D. BUST, M.B., B.S., BRUCE M. JONES, M.B., B.S., WILLIAM SALVESTER, M.B., B.S., GEOFF OUSTERHOUSE, M.B., B.S., AND KAREN SWICK, B.Sc.


N Engl J Med 2002; 346:557-563

- ### Benefits of Therapeutic Hypothermia
- Randomized controlled trial
 - Hypothermia for 12 hours (33°C) versus normothermia
 - Vfib arrest unresponsive after ROSC
 - Primary end-point: survival to hospital discharge to home or SNF
- N Engl J Med 2002; 346:557-563



BEDSIDE CONSIDERATIONS

11



Achieving Target Temperatures

Invasive Cooling	Non-Invasive Cooling
<ul style="list-style-type: none"> • Endovascular catheters • ECMO • Cold saline / fluid infusion 	<ul style="list-style-type: none"> • Immersion devices • Cooling pad / blanket devices • Ice packs
Benefits: <ul style="list-style-type: none"> • Faster cooling • Improved temperature control 	
Risks: <ul style="list-style-type: none"> • Procedure needed for placement • Fluid volume 	
<ul style="list-style-type: none"> • Less invasive • Most can be initiated earlier • Slow or incomplete cooling • May be cumbersome 	

13

Depth and Duration of Hypothermia

- Duration of hypothermia
 - Generally accepted 12-24 hours
- Temperature goal
 - Generally accepted range from 32° C to 34° C
 - Side effects increase with the decrease in temperature
- Targeted Temperature Management at 33° C versus 36° C After Cardiac Arrest

14

Depth and Duration of Hypothermia

THE NEW ENGLAND JOURNAL OF MEDICINE

ORIGINAL ARTICLE

Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest

Niklas Nielsen, M.D., Ph.D., Jens Wetterslev, M.D., Ph.D., Tobias Cronberg, M.D., Ph.D., David Erlinge, M.D., Ph.D., Yvan Gensini, M.D., Christian Hassager, M.D., D.M.Sc., Jamale Houra, M.D., Ph.D., Jun Kikuchi, M.D., Ph.D., Jørgen Kjergaard, M.D., D.M.Sc., Michael Kuisma, M.D., Ph.D., Tommaso Pilati, M.D., Pascal Stenmetz, M.D., Michael Waischer, M.D., Ph.D., Marc P. Wise, M.D., D.Phil., Anders Arnesen, M.D., Ph.D., Nawaf Al-Solaihi, M.D., Soren Egegaard, M.D., D.M.Sc., John Bro-Jorgensen, M.D., Jørgen Bourne, M.D., Jan-Fredrik Bugge, M.D., Ph.D., Christopher D. Kingdon, M.D., Nicole P. Juffermans, M.D., Ph.D., Mervyn Kouznetsov, B.N., M.Sc., Lars Kaber, M.D., D.M.Sc., Jørund Langager, M.D., Cvetka Lijak, O.T., Jacob Edou Mellor, M.D., D.M.Sc., Malin Ringden, M.D., Ph.D., Christian Rylander, M.D., Ph.D., Omid Sami, M.D., Christopher Warren, M.D., Pawlowski, M.D., D.M.Sc., and Hans Friberg, M.D., Ph.D., for the TTM Trial Investigators*

N Engl J Med 2013;369:2197-206

15

Depth and Duration of Hypothermia

- Randomized controlled trial
- Hypothermia for 28 hours at 33° C versus 36° C
- Out-of-hospital arrest unresponsive after ROSC with 20 minutes sustained ROSC
- Primary end-point: all cause mortality through the end of the trial

N Engl J Med 2013;369:2197-206

16

Depth and Duration of Hypothermia

Table 2. Outcomes.

Outcome	33° C Group no./total no. (%)	36° C Group no./total no. (%)	Hazard Ratio or Risk Ratio (95% CI)*	P Value
Primary outcome: Deaths at end of trial	235/473 (50)	225/466 (48)	1.06 (0.89-1.28)	0.51
Secondary outcomes				
Neurologic function at follow-up†				
CPC of 3-5	251/469 (54)	242/464 (52)	1.02 (0.88-1.16)	0.78
Modified Rankin scale score of 4-6	245/463 (52)	233/464 (50)	1.01 (0.89-1.14)	0.87
Deaths at 180 days	226/473 (48)	220/466 (47)	1.01 (0.87-1.15)	0.92

N Engl J Med 2013;369:2197-206

17

Depth and Duration of Hypothermia

N Engl J Med 2013;369:2197-206

18

Maintaining Target Temperatures

- Shivering
 - Bedside Shivering Assessment Scale
 - 0 **None**: no shivering noted on palpation of the masseter neck or chest wall.
 - 1 **Mild**: shivering localized to the neck and/or thorax.
 - 2 **Moderate**: shivering involves gross movement of the upper extremities.
 - 3 **Severe**: shivering involves gross movements of the trunk and upper and lower extremities.

Stroke. 2006;39:3247-3247.
J Cardiovasc Med. 2014; 15:000-000

19

Maintaining Target Temperatures

- Pharmacologic agents
 - Paralytics
 - Continuous infusion vs bolus dosing
 - Mask seizure symptoms
 - Sedation & Analgesia
 - Meperidine
 - Acetaminophen

20

Assessment Question

- What is the primary benefit of induced hypothermia after cardiac arrest?
 - a. Improved neurological outcome
 - b. Reduced myocardial damage
 - c. Decreased incidence of acute kidney failure
 - d. Avoidance of shock

21